Denise Yardley, MD, says one of the biggest challenges the malignancy poses is triple negative breast cancer's heterogeneity, resulting in medical professionals having to rely on clinical path features that do not provide enough preciseness in treatment.
Denise Yardley, MD, a medical oncologist at the Sarah Cannon Cancer Research Institute in Nashville, Tennessee, discusses the challenges of treating triple negative breast cancer. Yardley says one of the biggest challenges the malignancy poses is triple negative breast cancer's heterogeneity, resulting in medical professionals having to rely on clinical path features that do not provide enough preciseness in treatment.
Yardley adds that one of the keys to treating triple negative breast cancer is to segregate out different types of tumors that would respond to certain treatments. She also says that label "triple negative breast cancer" is not a "one-size-fits-all" type of breast cancer, and needs to be further explored by researchers.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More